Akero Therapeutics CEO gifts 74,538 AKRO shares, retains 436,837

Akero Therapeutics, Inc. insider ownership changed due to a charitable gift.

Rhea-AI Filing Summary

Akero Therapeutics, Inc. insider ownership changed due to a charitable gift. The company’s President, CEO, and director reported donating 74,538 shares of Akero Therapeutics common stock as a gift to a donor advised fund on 11/20/2025. The transaction was reported with a price of $0, consistent with a non-cash charitable transfer rather than a market sale.

Following this gift, the reporting person directly beneficially owns 436,837 shares of Akero Therapeutics common stock. This Form 4 filing documents the change in beneficial ownership for regulatory disclosure purposes and does not describe any open-market purchase or sale.

Insider Trade Summary

74,538 shares gifted

Gift 1 txn

Insider Cheng Andrew

Role President and CEO

Type	Security	Shares	Price	Value
Gift	Common Stock	74,538	$0.00	$0.00

Holdings After Transaction: Common Stock — 436,837 shares (Direct)

Footnotes (1)

1. F1. Represents shares of the Issuer's Common Stock that the reporting person donated as a gift to a donor advised fund.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Akero Therapeutics (AKRO) report on this Form 4?

The President, CEO, and director of Akero Therapeutics (AKRO) reported a transaction dated 11/20/2025 involving common stock categorized under transaction code G, which indicates a gift of shares.

How many Akero Therapeutics (AKRO) shares were transferred in the reported gift?

The reporting person transferred 74,538 shares of Akero Therapeutics common stock as a gift, with the transaction recorded at a price of $0 per share.

Who received the gifted Akero Therapeutics (AKRO) shares?

The filing states that the 74,538 shares of Akero Therapeutics common stock were donated as a gift to a donor advised fund.

How many Akero Therapeutics (AKRO) shares does the insider own after the transaction?

After the reported gift, the insider directly beneficially owns 436,837 shares of Akero Therapeutics common stock, reported as direct (D) ownership.

What is the role of the reporting person at Akero Therapeutics (AKRO)?

The reporting person is identified as a director and an officer, serving as President and CEO of Akero Therapeutics, Inc.

Does this Akero Therapeutics (AKRO) Form 4 report any option or derivative transactions?

The section for derivative securities is present but contains no reported acquisitions or disposals, indicating only common stock was involved in this transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/21/2025 - 06:25 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cheng Andrew

(Last) (First) (Middle)

C/O AKERO THERAPEUTICS, INC.

601 GATEWAY BOULEVARD, SUITE 350

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Akero Therapeutics, Inc. [ AKRO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
11/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/20/2025		G(1)		74,538	D	$0	436,837	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of the Issuer's Common Stock that the reporting person donated as a gift to a donor advised fund.

	/s/ Jonathan Young, Attorney-in-Fact	11/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.